FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasiliigton,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* PACE GARY W						2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	•	irst) CIENCES, INC.	(Middle)			Date (iest Trans	action (Month/Day/Year)					Officer below)	(give title		Other (s below)	specify	
5401 WEST KENNEDY BOULEVARD, SUITE 890					4.1	If Amendment, Date of Original Filed (Month/Day/Year)								ndividual or 3	Joint/Group	Filing	(Check Ap	plicable	
(Street) TAMPA	Fl	Ĺ	33609											Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
		Tab	ole I - No	n-Deri	vativ	e Se	curit	ies Ac	quired	, Dis	sposed o	f, or Be	neficial	ly Owned					
		2. Transaction Date (Month/Day/Year)		ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			Benefici Owned I	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) (Instr. 3 and 4)			(1130.14)			
Common	Stock			02/28	02/28/2022				M		9,807	A	\$11.0	\$11.02 139,33		D			
Common Stock		02/28	02/28/2022				M		18,834	A	\$11.0	2 158	8,171		D				
Common Stock			02/28	2/28/2022				S		28,641	D	\$66.83	(1) 129	129,530		D			
Common Stock			03/01	3/01/2022				M		193	A	\$11.0	2 129	129,723		D			
Common Stock 0			03/01	1/2022				M		1,166	A	\$11.0	2 130	130,889		D			
Common Stock 03/01/2			L/2022	2022		S		1,359 D S		\$67.7	5 129	129,530		D					
		-	Table II -								osed of, convertil			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) if	3A. Deem Execution if any (Month/Da	Date,	4. Transacti Code (Ins 8)		on of		6. Date Exerci Expiration Dat (Month/Day/Ye		e of Securitie		es g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$11.02	02/28/2022			M			9,807	(2)		04/02/2022	Common Stock	9,807	\$0.00	193		D		
Stock Option (Right to Buy)	\$11.02	02/28/2022			M			18,834	(3)		04/02/2022	Common Stock	18,834	\$0.00	1,166		D		
Stock Option (Right to Buy)	\$11.02	03/01/2022			M			193	(2)		04/02/2022	Common Stock	193	\$0.00		D			
Stock Option (Right to Buy)	\$11.02	03/01/2022			M			1,166	(3)		04/02/2022	Common Stock	1,166	\$0.00	0		D		

Explanation of Responses:

- 1. he price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$66.750 to \$67.155, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges so forth in this footnote.
- $2. \ The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on May 3, 2012.$
- 3. The option vested and became exercisable as to 25% of the option shares on April 3, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.

Remarks:

/s/ Kristen Williams, Attorney-

in-Fact

** Signature of Reporting Person

03/01/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.